The healthcare arm of the Asia-Pacific health-services provider DKSH has launched a three-part whitepaper series titled “2025 Whitepaper Series on Commercial Go-To-Model Trends,” aimed at guiding pharmaceutical, biotech and MedTech companies to rethink traditional commercial strategies across APAC.
The report argues that in a region facing fragmented healthcare systems, complex regulation, uneven access and rising demand, conventional in-house commercialization models — reliant on large infrastructure investment — often struggle to deliver efficient, equitable access to therapies.
According to the whitepaper, strategic outsourcing partnerships can deliver sustainable growth, resource agility and improved patient access — enabling companies to navigate regulatory and pricing challenges without heavy fixed investment.
Research underpinning the report included a survey of over 50 senior leaders from pharmaceuticals, biotech and medical-device firms, along with in-depth interviews of top industry decision-makers.
The whitepaper outlines why traditional commercial models are faltering, how companies can assess which product portfolios and commercial functions yield the most value when outsourced, and what governance, data readiness and digital tools are needed to maintain high-performing outsourcing partnerships over time.
The findings show that 90 % of executives surveyed already outsource at least part of their business, and 62 % have increased outsourcing over the past three years — underlining the growing shift toward outsourced commercial models in the region.
DKSH positions this white-paper release as a response to APAC’s otherwise under-invested healthcare markets, suggesting that outsourcing may be the key to unlocking the region’s estimated US$10 billion healthcare-outsourcing opportunity — and improving timely patient access to vital therapies and treatments.
